Investigating Psychiatric Adverse Effects of GLP-1 Agonists
European medicines regulators call for further investigation into potential psychiatric adverse effects associated with GLP-1 receptor agonists, highlighting the need for heightened vigilance in monitoring patient safety.
August 2024